Uncategorized

Eisai to Present New Data From LEQEMBI® (lecanemab-irmb) Phase 3 Clarity AD Study and Other Alzheimer’s Disease Pipeline Research at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Eisai Co. Ltd announced that the company will present new data from the phase 3 Clarity AD study for its Alzheimer’s disease treatment LEQEMBI® 100 mg/mL injection for intravenous use and new data on the subcutaneous formulation in development at the 16th annual Clinical Trials on Alzheimer’s Disease conference.

Eisai to Present New Data From LEQEMBI® (lecanemab-irmb) Phase 3 Clarity AD Study and Other Alzheimer’s Disease Pipeline Research at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference Read More »

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development

LegoChem Biosciences Inc. and Glycotope GmbH have entered into an exclusive worldwide licensing agreement to develop an antibody drug conjugate by combining LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies, building on a previously announced 2022 collaboration and license agreement.

LegoChem Biosciences Enters Worldwide Licensing Agreement with Glycotope for Antibody Drug Conjugate Development Read More »

Scroll to Top